Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Notes underwriting agrmnt
|
|
Ayala Pharmaceuticals, Inc. (ADXS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/29/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 09/29/2023 |
3/A
| Form 3/A - Initial statement of beneficial ownership of securities: [Amend] |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
SC 13G
| Redmile Group, LLC reports a 6.8% stake in AYALA PHARMACEUTICALS, Inc. |
| 01/30/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 01/30/2023 |
3
| aMoon Growth Fund Limited Partnership (10% Owner) has filed a Form 3 on Ayala Pharmaceuticals, Inc. |
| 01/30/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Interactive Data |
| 01/30/2023 |
SC 13G
| Schindel Yair Chaim reports a 12.2% stake in Ayala Pharmaceutics, Inc |
| 01/25/2023 |
8-K
| Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; Election of Directors; Appoin... |
| 01/23/2023 |
4
| SIDRANSKY DAVID (Director) has filed a Form 4 on Ayala Pharmaceuticals, Inc.|
Txns:
| Granted 46 shares
@ $0
Granted 2,342 options
@ $55.23, valued at
$129.3k
Granted 2,342 options
@ $8.7, valued at
$20.4k
|
|
| 01/23/2023 |
4
| GOLDBERG MURRAY A (Director) has filed a Form 4 on Ayala Pharmaceuticals, Inc.|
Txns:
| Granted 3,279 options
@ $27.21, valued at
$89.2k
Granted 2,342 options
@ $47.17, valued at
$110.5k
Granted 1,171 options
@ $55.23, valued at
$64.7k
Granted 1,171 options
@ $8.7, valued at
$10.2k
|
|
| 01/23/2023 |
4
| Bisker-Leib Vered (Director) has filed a Form 4 on Ayala Pharmaceuticals, Inc.|
Txns:
| Granted 1,639 options
@ $58.59, valued at
$96k
Granted 1,171 options
@ $55.23, valued at
$64.7k
Granted 1,171 options
@ $8.69, valued at
$10.2k
|
|
| 01/23/2023 |
4
| Spiegel Robert J. (Director) has filed a Form 4 on Ayala Pharmaceuticals, Inc.|
Txns:
| Granted 3,279 options
@ $27.21, valued at
$89.2k
Granted 2,342 options
@ $47.17, valued at
$110.5k
Granted 1,171 options
@ $55.23, valued at
$64.7k
Granted 1,171 options
@ $8.7, valued at
$10.2k
|
|
| 01/23/2023 |
3
| GOLDBERG MURRAY A (Director) has filed a Form 3 on Ayala Pharmaceuticals, Inc. |
| 01/23/2023 |
3
| Bisker-Leib Vered (Director) has filed a Form 3 on Ayala Pharmaceuticals, Inc. |
| 01/23/2023 |
3
| Spiegel Robert J. (Director) has filed a Form 3 on Ayala Pharmaceuticals, Inc. |
| 01/13/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure Interactive Data |
| 01/12/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/12/2023 |
8-K
| Other Events Interactive Data |
| 12/13/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 12/12/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 12/12/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 12/08/2022 |
S-4/A
| Form S-4/A - Registration of securities, business combinations: [Amend] |
| 12/02/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 12/02/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/02/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...|
Docs:
|
"ADVAXIS, INC. CERTIFICATE OF DESIGNATION OF SERIES E PREFERRED STOCK Pursuant to Section 151 of the General Corporation Law of the State of Delaware THE UNDERSIGNED DOES HEREBY CERTIFY, on behalf of Advaxis, Inc., a Delaware corporation , that the following resolution was duly adopted by the board of directors of the Corporation , in accordance with the provisions of Section 151 of the General Corporation Law of the State of Delaware, as amended on November 16, 2022, which resolution provides for the creation of a series of the Corporation’ s Preferred Stock, par value $0.001 per share, which is designated as “Series E Preferred Stock,” with the rights, preferences, privileges and restrictions set forth therein. WHEREAS, the Amended and Restated Certificate of Incorporation of the Corporat...",
"SECURITIES PURCHASE AGREEMENT" |
|
| 11/29/2022 |
S-4
| Form S-4 - Registration of securities, business combinations: |
| 10/19/2022 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 10/19/2022 |
8-K
| Quarterly results |
| 07/01/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
RW
| Form RW - Registration Withdrawal Request: |
| 06/24/2022 |
8-K
| Quarterly results |
| 06/10/2022 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
|
|
|